NCT03368196View on ClinicalTrials.gov

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 2, 2018

Primary Completion Date

September 14, 2018

Study Completion Date

September 28, 2022

Conditions
Adenocarcinoma, GastricNeoplasm, Breast
Interventions
DRUG

DS-8201a

An antibody drug conjugate

Trial Locations (2)

100

National Taiwan University Hospital, Taipei

112

Taipei Veterans General Hospital, Taipei

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company

INDUSTRY

NCT03368196 - DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein | Biotech Hunter | Biotech Hunter